

12309

1634

PATENT
Attorney Docket No. PRMG-06684

RECEIVED
TECH CENTER 1600/2900

02 APR 26 PM 2:38

TECH CENTER 1600/2900

APR 29 2002

#8
4/30/02
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John W. Shultz *et al.*

Serial No.: 09/995,912

Filed: 11/28/01

Entitled: RNA Polymers And Uses Thereof

Group No.:

Examiner: A. Chakrabarti

INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being sent via Federal Express to be delivered to Examiner Arun Chakrabarti.

Dated: April 25, 2002


By: Mary Ellen Waite
Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

This Information Disclosure Statement is being filed before the issuance of a first Office Action and therefore Applicant's believe no fee is required. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: April 25, 2002



David A. Casimir
Registration No. 42,395

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John W. Shultz *et al.*

Serial No.: 09/995,912

Filed: 11/28/01

Entitled: RNA Polymers And Uses Thereof

Group No.:

Examiner:

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being sent via Federal Express to be delivered to Examiner Arun Chakrabarti..

Date: April 25, 2002

By:

Mary Ellen Waite
Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications are referred to in the body of the specification:

- U.S. Patent No. 4,683,195
- U.S. Patent No. 4,683,202
- U.S. Patent No. 4,965,188
- U.S. Patent No. 5,496,546
- U.S. Patent No. 5,705,188
- WO 97/30731
- Badet *et al.*, PNAS, 86:8427 [1989]. This reference is not be supplied at this time but will be supplied as soon as possible.
- Wechsel *et al.*, Anticancer Res., 19:1537 [1999]
- Gho and Chae, J. Biol. Chem., 272:24294 [1997]
- Piccoli *et al.*, PNAS, 95:4579 [1998]

RECEIVED

APR 29 2002

TECH CENTER 1600/2900
02 APR 26 PM 2:39

RECEIVED
TECH CENTER 1600/2900

- Olson *et al.*, PNAS, 92:442 [1995]
- Gho *et al.*, Cancer Res., 57:3733 [1997]
- Shein, Nat. Biotechnol. 15(6):529-36 (1997)
- Montero *et al.*, Clin Cancer Res., 5:3722 [1999]
- Hartmann *et al.*, Cancer Res., 59:1578 [1999]
- Miyake *et al.*, Cancer, 86:316 [1999].
- Eberle *et al.*, Anticancer Res., 20:1679 [2000].
- Shimoyama and Kaminishi, J. Cancer Res. Clin. Oncol., 126:468 [2000].
- Barton *et al.*, Clin. Cancer Res., 3:1579 [1997].

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- U.S. Patent No. 5,776,690
- WO 93/08291
- EP 1 050 587 A2
- Anderson and Young, Quantitative Filter Hybridization, in *Nucleic Acid Hybridization* [1985]. This reference is a book and will be supplied at the Examiner's request.
- Wetmur, Crit. Rev. Biochem. and Mol. Biol. 26:227-[1991]. This reference is not be supplied at this time but will be supplied as soon as possible.
- Delcardayre *et al.*, Protein Engineering, 8:261 [1995]. This reference is not be supplied at this time but will be supplied as soon as possible.
- Rahman *et al.* Anal. Chem., 68:134 [1996]. This reference is not be supplied at this time but will be supplied as soon as possible.
- Lloveras *et al.*, Clin. Cancer Res. 5:1125-1130 (1999). This reference is not be supplied at this time but will be supplied as soon as possible.
- Verselis *et al.*, Biochem Biophys Res. Commun. 27;259(1):178-84 (1999)
- Leonidas *et al.*, J. Mol. Biol. 22;285(3):1209-33 (1999)
- Cockerill *et al.*, Int Rev Cytol 159:113-60 (1995)
- Schneider *et al.*, Cytogenet Cell Genet 59(4):264-7 (1992)
- Bertolini *et al.*, Br J Haematol 106(2):504-9 (1999)

- Chopra *et al.*, Cancer Invest 16(3):152-9 (1998)
- Olson *et al.*, Biochem Biophys Res Commun 26;242(3):480-3 (1998)
- RNase OUT™ Recombinant Ribonuclease Inhibitor, Life Technoogies,
http://order.lifetech.com/liti_store...rderidentifier=ID966619090890572376
- Poly(I)*Poly(C), Amersham Pharmacia Biotech, pg. 88
- Poly(I)*Poly(C), Amersham Pharmacia Biotech, CATS Tue, Aug 01 2000
- RNAGuard Ribonuclease Inhibitor (Procine),
<http://www.apbiotech.com/stiboasp/showmodule.asp?nModuleid=4140>
- SUPERase-In: the ULtimate RNase Inhibitor, Ribonuclease Inhibitor PRotein (RIP) Is No Longer The Best Ribonuclease Inhibitor,
<http://www.ambion.com/superasein/Page2.html>
- Wu *et al.*, Amer Soc for Biochem and Olecular Biol., Inc. 270:17476-17481 (1995)
- Hilleman, Journal of Infectious Diseases, 121:196-211 (1970)
- Field *et al.*, PNAS 58:1004-1010 (1967)
- Baugh *et al.*, Div. of Virus and Cell Biol Res., 1194-1198 (1971)
- Fehlmann *et al.*, Clinical Chemistry 39:368-396 (1993)
- Buolamwini, Chemical Biology 3:500-509 (1999)
- Levy *et al.*, Medical Sciences 62:357-361 (1969)
- Soncin *et al.*, J. of Biological Chemistry 272:9818-9824 (1997)
- Panganiban *et al.*, J. of Biological Chemistry 258:12487-12493 (1983)
- Rabson *et al.*, Nat. Cancer Inst. 495-497 (1969)
- Wells *et al.*, J. of Biological Chemistry 159:1363-1370 (1964)
- Nathan *et al.*, Focus 19:50-51 (1997)

PATENT

Attorney Docket No. **PRMG-06684**

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: April 25, 2002



David A. Casimir
Registration No. 42,395
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900